MET vs SRNE · P/E 13, rev $38.23B vs $385.9K cap
MetLife Inc (MET) versus Sorrento Therape (SRNE) — a side-by-side from cached financials, not a winner call.
MetLife Inc (MET) is a insurance - life company listed on US.
Sorrento Therape (SRNE) is a biotechnology company listed on OTCQB.
Latest reported MET revenue for 2026-06-30 was $38.23B. Net income was $1.92B. MET currently screens at market cap $52.16B and trailing P/E 12.7.
SRNE does not have a complete income-statement cache yet.
MET currently screens at market cap $52.16B and trailing P/E 12.7. SRNE currently screens at market cap $385.9K.
Not investment advice. Open the MET and SRNE stock pages for the full models.
Not investment advice.